| | [Table 19] |
|---|
| | 3rd Quarter 2010 | 3rd Quarter 2011 | First Nine Months 2010 | First Nine Months 2011 |
| | € million | € million | € million | € million |
| Net sales | 8,581 | 8,670 | 26,076 | 27,337 |
| Cost of goods sold | (4,166) | (4,278) | (12,627) | (13,233) |
| Gross profit | 4,415 | 4,392 | 13,449 | 14,104 |
| | | | | |
| Selling expenses | (2,171) | (2,134) | (6,395) | (6,511) |
| Research and development expenses | (776) | (691) | (2,240) | (2,155) |
| General administration expenses | (404) | (403) | (1,243) | (1,254) |
| Other operating income | 230 | 92 | 436 | 573 |
| Other operating expenses | (730) | (157) | (1,328) | (1,237) |
| Operating result [EBIT] | 564 | 1,099 | 2,679 | 3,520 |
| | | | | |
| Equity-method loss | (13) | (12) | (45) | (33) |
| Non-operating income | 76 | 153 | 391 | 387 |
| Non-operating expenses | (330) | (365) | (1,118) | (962) |
| Non-operating result | (267) | (224) | (772) | (608) |
| | | | | |
| Income before income taxes | 297 | 875 | 1,907 | 2,912 |
| | | | | |
| Income taxes | (7) | (229) | (456) | (837) |
| | | | | |
| Income after taxes | 290 | 646 | 1,451 | 2,075 |
| of which attributable to non-controlling interest | 5 | 4 | 5 | 2 |
| of which attributable to Bayer AG stockholders (net income) | 285 | 642 | 1,446 | 2,073 |
| | | | | |
| | € | € | € | € |
| Earnings per share | | | | |
| Basic | 0.35 | 0.78 | 1.75 | 2.51 |
| Diluted | 0.35 | 0.78 | 1.75 | 2.51 |
| 2010 figures restated |